CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
SAGE-547drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02052739
NCT02052739Phase 2Completed
CompareCT.gov

An Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

Supernus Pharmaceuticals, Inc.·interventional·Posted Feb 3, 2014·Updated Sep 15, 2025

In Brief

A Phase 2 clinical trial evaluating SAGE-547 for Super-refractory Status Epilepticus. Completed, enrolled 25 participants across 17 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and tolerability of SAGE-547 in participants in super-refractory status epilepticus (SRSE).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSuper-refractory Status Epilepticus
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 3, 2014
Enrollment StartMar 21, 2014
Primary CompletionMay 3, 2015
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 12.4 years ago

Interventions

SAGE-547drug

Solution for injection for IV infusion